But Point32Healths executive chair, Eileen Auen, last month said the insurer planned to make Zepbound its preferred exclusive GLP-1 drug for the treatment of obesity, starting in July
The overwhelming majoritymore than 80 percentof Plaintiffs in this MDL allege gastroparesis as an injury
Retatrutide is undergoing further research to evaluate its long-term cardiovascular benefits, neuroprotective potential, and impact on metabolic diseases
Patients considering GLP-1 therapy should understand that any joint pain improvement is likely a secondary benefit rather than a primary therapeutic target
placebo in patients who were overweight or obese and showed sustained, clinically relevant weight loss and improvement in lipid parameters
also reported a low risk of hypoglycemia, with events occurring in similar proportions of patients with obesity but without diabetes who were treated with liraglutide 3.0 mg (1.3%) compared with placebo (1.0%) [37]